SEC Form 4 · accession 0001513162-15-000351
Anixa Biosciences Inc · ANIX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert Andrew Berman
Officer — President and CEO · Director
Period of report
Jun 15, 2015
Accepted (ET)
Jun 18, 2015 · 4:42 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000715446
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 15, 2015 | P | 30,000 | $0.136 | A | 753,650 | D | |
| Common StockF2 | Jun 17, 2015 | P | 50,000 | $0.1349 | A | 803,650 | D | |
| Common StockF3 | Jun 18, 2015 | P | 50,000 | $0.1297 | A | 853,650 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.1320 to $0.1399, inclusive. The reporting person undertakes to provide to ITUS Corporation, any security holder of ITUS Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth.
- F2The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.1240 to $0.1450, inclusive. The reporting person undertakes to provide to ITUS Corporation, any security holder of ITUS Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth.
- F3The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.1285 to $0.1325, inclusive. The reporting person undertakes to provide to ITUS Corporation, any security holder of ITUS Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth.